Keytruda pembrolizumab: Additional Phase Ib data

Data from 26 heavily pretreated patients with salivary gland carcinoma in the open-label, international Phase Ib KEYNOTE-028 trial showed that 10 mg/kg IV Keytruda every 2 weeks for up to 2 years led ...